Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

[1]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[2]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[3]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[4]  L. Amler,et al.  PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients , 2015, British Journal of Cancer.

[5]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[6]  Jian Huang,et al.  PD-L1 and Survival in Solid Tumors: A Meta-Analysis , 2015, PloS one.

[7]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[8]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[9]  G. Freeman,et al.  Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study , 2015, Journal of Immunotherapy for Cancer.

[10]  A. Errico.  Immunotherapy: PD-1–PD-L1 axis: efficient checkpoint blockade against cancer , 2015, Nature Reviews Clinical Oncology.

[11]  M. Landers,et al.  Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization , 2015, Journal of circulating biomarkers.

[12]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[13]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[14]  M. Postow,et al.  Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway , 2014, Pharmacogenomics and personalized medicine.

[15]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[16]  Yu Cao,et al.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.

[17]  G. Silverman,et al.  Programmed death-1 pathway in cancer and autoimmunity. , 2014, Clinical immunology.

[18]  I. Melero,et al.  Orchestrating immune check-point blockade for cancer immunotherapy in combinations. , 2014, Current opinion in immunology.

[19]  C. Swanton,et al.  Implications of intratumour heterogeneity for treatment stratification , 2014, The Journal of pathology.

[20]  T. Okazaki,et al.  A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application , 2013, Nature Immunology.

[21]  Corbin E. Meacham,et al.  Tumour heterogeneity and cancer cell plasticity , 2013, Nature.

[22]  Mark J. Ratain,et al.  Tumour heterogeneity in the clinic , 2013, Nature.

[23]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[24]  Harris Markomanolaki,et al.  Apoptotic Circulating Tumor Cells in Early and Metastatic Breast Cancer Patients , 2013, Molecular Cancer Therapeutics.

[25]  M. Razzak.  From ASCO—targeted therapies: Anti-PD-1 approaches—important steps forward in metastatic melanoma , 2013, Nature Reviews Clinical Oncology.

[26]  J. Taube,et al.  Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody , 2012, Clinical Cancer Research.

[27]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[28]  R. Sylvester,et al.  Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Olson,et al.  How apoptotic cells aid in the removal of their own cold dead bodies , 2012, Cell Death and Differentiation.

[30]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[31]  Peter Kuhn,et al.  Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors , 2012, Physical biology.

[32]  Joshua M. Kunken,et al.  Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers , 2012, Physical biology.

[33]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[34]  B. Ksander,et al.  Tumor Cell Programmed Death Ligand 1-Mediated T Cell Suppression Is Overcome by Coexpression of CD80 , 2011, The Journal of Immunology.

[35]  M. Parmar,et al.  International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  L. Kiemeney,et al.  The present and future burden of urinary bladder cancer in the world , 2009, World Journal of Urology.

[37]  G. Rassidakis,et al.  Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma , 2004, Leukemia.

[38]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  T. Hirano,et al.  Relationship between chromosomal instability and intratumoral regional DNA ploidy heterogeneity in primary gastric cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  R. Lash,et al.  Intratumoral heterogeneity of DNA ploidy in breast carcinomas: a flow cytometric assessment of sampling techniques. , 1995, Cytometry.

[41]  M. Atkins,et al.  Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. , 2015, International immunology.

[42]  Charles G. Drake,et al.  Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer , 2014, Nature Reviews Clinical Oncology.

[43]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[44]  L. Collette,et al.  Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. , 2006, European journal of cancer.

[45]  K. Sasaki,et al.  Intratumoral heterogeneity in DNA ploidy of bladder carcinomas. , 1992, Oncology.

[46]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.